ALX Oncology (ALXO) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ALX Oncology (ALXO) has outperformed Korro Bio (KRRO) over the past year, losing 35.6% versus a loss of 78.3%. Over five years, KRRO leads with a -97.1% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $149.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | KRRO |
|---|---|---|
| Share price | $1.25 | $10.16 |
| Market cap | $172.85M | $149.61M |
| 1-day change | +5.93% | -3.97% |
| YTD return | +10.62% | +26.84% |
| 1-year return | -35.57% | -78.26% |
| 5-year return | -97.88% | -97.14% |
| EPS (TTM) | $-1.13 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $55.89 |
| 52-week low | $1.05 | $5.20 |
| Distance from 52-week high | -53.01% | -81.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +268.00% | +98.82% |
| Average volume | 1.05M | 147.29K |
| Shares outstanding | 138.28M | 14.73M |
| Employees | 48 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed KRRO by 42.7 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ALXO vs KRRO FAQ
Which is bigger, ALX Oncology or Korro Bio?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $149.61M for Korro Bio (KRRO).
Which stock has performed better over the past year, ALXO or KRRO?
ALXO returned -35.57% over the past 12 months, compared with -78.26% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.